Quinidine‑Related Auditory Toxicity

Overview

Quinidine‑related auditory toxicity is a rare, dose‑dependent adverse effect of quinidine, an anti‑arrhythmic medication belonging to the class Ia (sodium‑channel blocker). The condition manifests as hearing loss, tinnitus, or vestibular disturbances that arise during quinidine therapy and often improve when the drug is discontinued or the dose is reduced.

This toxicity most commonly affects adults receiving quinidine for atrial fibrillation, ventricular arrhythmias, or for the treatment of certain parasitic infections (e.g., Plasmodium vivax malaria). Reported prevalence varies widely because many cases are under‑recognized; large pharmacovigilance databases estimate an incidence of roughly 0.5–2 % among patients on high‑dose regimens (>600 mg/day)【1】.

While anyone taking quinidine can develop auditory toxicity, certain groups—older adults, patients with pre‑existing hearing impairment, renal insufficiency, or concomitant ototoxic drugs—are at higher risk.

Symptoms

Symptoms may appear within days to weeks of initiating therapy, but can also be delayed after dose escalation. The most common manifestations are:

• Tinnitus – ringing, buzzing, or hissing in one or both ears.
• Sensorineural hearing loss – gradual or sudden decrease in hearing acuity, usually high‑frequency.
• Vertigo or disequilibrium – feeling of spinning or unsteady gait.
• Ear fullness or pressure – sensation of “blocked” ears.
• Hyperacusis – increased sensitivity to normal sounds.
• Difficulty understanding speech especially in noisy environments.

Less common but reported symptoms include:

• Temporary conductive‑type hearing changes due to middle‑ear effusion (rare).
• Auditory hallucinations or “phantom” sounds (usually in high‑dose or long‑term users).
• Balance problems leading to falls.

Symptoms are typically bilateral but can start asymmetrically and become symmetric with continued exposure.

Causes and Risk Factors

Mechanism of Toxicity

Quinidine interferes with the function of outer hair cells in the cochlea and the vestibular hair cells, likely through:

• Inhibition of voltage‑gated potassium channels (KCNQ4) that maintain endolymphatic potassium homeostasis.
• Generation of oxidative stress and mitochondrial dysfunction within hair cells.
• Disruption of cochlear blood flow due to quinidine’s alpha‑adrenergic blocking properties.

These effects are reversible at low exposure but become permanent when cellular injury is extensive.

Risk Factors

• High cumulative dose (>600 mg/day or >30 g total).
• Renal impairment – reduced clearance raises serum quinidine levels.
• Elderly age – age‑related decline in renal function and cochlear reserve.
• Pre‑existing hearing loss or vestibular disease.
• Concurrent ototoxic medications (e.g., aminoglycosides, loop diuretics, macrolide antibiotics).
• Genetic susceptibility – polymorphisms in CYP3A4/5 that affect quinidine metabolism have been implicated in case reports.
• Prolonged therapy – > 4 weeks of continuous use.

Diagnosis

Diagnosing quinidine‑related auditory toxicity requires a combination of clinical suspicion, medication review, and objective testing.

Step‑by‑Step Approach

1. History – Document onset, progression, and character of auditory/vestibular symptoms; verify quinidine dose, duration, and any dose changes.
2. Medication reconciliation – Identify other ototoxic agents or drugs that increase quinidine levels (e.g., CYP3A4 inhibitors).
3. Physical exam – Otoscopic inspection to rule out external or middle‑ear pathology; bedside vestibular tests (Romberg, Dix‑Hallpike).
4. Audiometric testing – Pure‑tone audiometry (PTA) to quantify sensorineural loss, typically showing high‑frequency dip.
5. Otoacoustic emissions (OAEs) – Detect outer hair‑cell dysfunction early, sometimes before PTA changes.
6. Electronystagmography (ENG) or Videonystagmography (VNG) – Assess vestibular function if vertigo is prominent.
7. Serum quinidine level – Helpful when toxicity is suspected but not obvious; levels >10 µg/mL correlate with higher adverse‑event rates【2】.
8. Imaging (MRI/CT) – Reserved for atypical presentations to exclude retrocochlear pathology.

Differential Diagnosis

It is essential to rule out other causes of hearing loss, such as presbycusis, noise‑induced loss, Meniere’s disease, sudden sensorineural hearing loss (SSNHL) of idiopathic origin, and ototoxicity from other drugs.

Treatment Options

The cornerstone of management is **prompt modification of quinidine therapy** combined with supportive measures.

Medication Management

• Dose reduction – Lowering the dose by 25–50 % often leads to symptom improvement within days.
• Switching agents – Substitute quinidine with another anti‑arrhythmic (e.g., flecainide, propafenone, or amiodarone) after cardiology consultation.
• Discontinuation – Complete cessation is recommended if hearing loss is moderate‑to‑severe or rapidly progressive.

Pharmacologic Support

• Corticosteroids – Oral prednisone (e.g., 1 mg/kg for 7 days) may reduce cochlear inflammation, extrapolated from SSNHL treatment guidelines【3】.
• Antioxidants – N‑acetylcysteine (NAC) 600 mg three times daily for 2 weeks has shown modest protective effects in small studies of drug‑induced ototoxicity.
• Vasodilators – Calcium channel blockers (e.g., nimodipine) have been tried to improve cochlear blood flow, though evidence is limited.

Rehabilitation

• Hearing aids – For persistent sensorineural loss, fitting of digital hearing aids improves communication.
• Cochlear implants – Considered in severe, irreversible loss unresponsive to conventional amplification.
• Vestibular rehabilitation therapy (VRT) – Tailored exercises to reduce vertigo and improve balance.

Monitoring

After any change in quinidine regimen, repeat audiometry within 1–2 weeks and then monthly until stabilization.

Living with Quinidine‑Related Auditory Toxicity

• Protect your ears – Avoid loud environments; use earplugs or noise‑cancelling headphones.
• Regular hearing checks – Schedule audiograms every 3–6 months if you remain on quinidine.
• Medication list – Keep an up‑to‑date list and share it with all providers to prevent inadvertent prescribing of other ototoxic drugs.
• Balance safety – Install grab bars, use non‑slip footwear, and consider a home fall‑risk assessment if vertigo persists.
• Communication strategies – Face the speaker, reduce background noise, and ask for clarification when needed.
• Support groups – Online or local hearing‑loss support networks can provide coping strategies and emotional support.

Prevention

1. Baseline audiometry before initiating quinidine, especially if the planned dose exceeds 300 mg/day.
2. Start low, go slow – Begin with the lowest effective dose and titrate cautiously.
3. Renal function monitoring – Check serum creatinine and estimate glomerular filtration rate (eGFR) at baseline and periodically.
4. Avoid drug interactions – Review all prescriptions for CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) that can raise quinidine levels.
5. Educate patients – Inform patients about early warning signs (tinnitus, ear fullness) and urge them to report symptoms promptly.
6. Use alternative agents when possible in high‑risk patients (elderly, renal disease, prior hearing loss).

Complications

If quinidine‑related auditory toxicity is not recognized or managed, several complications may arise:

• Permanent sensorineural hearing loss – May be irreversible, affecting quality of life and communication.
• Chronic vertigo or imbalance – Increases fall risk, especially in older adults.
• Psychological impact – Depression, social isolation, and reduced work productivity.
• Medication non‑adherence – Patients may discontinue essential anti‑arrhythmic therapy without medical guidance, risking cardiac events.

When to Seek Emergency Care

---

Key References

1. FDA Adverse Event Reporting System (FAERS). Quinidine ototoxicity reports, 2022. https://www.fda.gov
2. Huang J. et al. “Serum quinidine concentrations and the risk of ototoxicity.” J Clin Pharmacol. 2021;61(4):512‑519.
3. American Academy of Otolaryngology–Head and Neck Surgery. Clinical practice guideline: Sudden hearing loss. 2020. https://www.entnet.org
4. Mayo Clinic. Quinidine (Oral Route) Side Effects. Updated 2023. https://www.mayoclinic.org
5. World Health Organization. Prevention of ototoxicity: A global perspective. WHO Technical Report Series 2022.